PUBLICATION

Osteomodulin downregulation is associated with osteoarthritis development

Authors
Zappia, J., Tong, Q., Van der Cruyssen, R., Cornelis, F.M.F., Lambert, C., Pinto Coelho, T., Grisart, J., Kague, E., Lories, R.J., Muller, M., Elewaut, D., Hammond, C.L., Sanchez, C., Henrotin, Y.
ID
ZDB-PUB-231002-71
Date
2023
Source
Bone research   11: 4949 (Journal)
Registered Authors
Hammond, Chrissy
Keywords
none
MeSH Terms
  • Animals
  • Down-Regulation
  • Male
  • Mice
  • Osteoarthritis*/genetics
  • Proteoglycans
  • Sclerosis
  • Zebrafish*
PubMed
37730805 Full text @ Bone Res
Abstract
Abnormal subchondral bone remodeling leading to sclerosis is a main feature of osteoarthritis (OA), and osteomodulin (OMD), a proteoglycan involved in extracellular matrix mineralization, is associated with the sclerotic phenotype. However, the functions of OMD remain poorly understood, specifically in vivo. We used Omd knockout and overexpressing male mice and mutant zebrafish to study its roles in bone and cartilage metabolism and in the development of OA. The expression of Omd is deeply correlated with bone and cartilage microarchitectures affecting the bone volume and the onset of subchondral bone sclerosis and spontaneous cartilage lesions. Mechanistically, OMD binds to RANKL and inhibits osteoclastogenesis, thus controlling the balance of bone remodeling. In conclusion, OMD is a key factor in subchondral bone sclerosis associated with OA. It participates in bone and cartilage homeostasis by acting on the regulation of osteoclastogenesis. Targeting OMD may be a promising new and personalized approach for OA.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping